Clinical value of herbal terpenes after extracorporeal shock-wave therapy


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Rowatinex is a combined drug based on plant terpenes which provides diuretic, anti-inflammatory and antispasmodic effect. A use of herbal preparation Rowatinex in patients with urinary stone disease after extracorporeal shock-wave therapy (ESWL) is analyzed in the article. Aim. To clarify the efficiency of the drug Rowatinex in patients with urinary stone disease after ESWL. Materials and methods. All patients were divided into two groups depending on therapy administered after ESWL. In main group (n=150) patients received Rowatinex, while in control group (n=70), antispasmodics were administered. Spontaneous passage offragments was observed in 104 patients in main group (69.3%) and 30 patients in control group (42.9%). Results. When studying the effect of therapy on the changes of complete blood count, biochemical panel and daily excretion of some substances (magnesium, uric acid, calcium, etc) there were no significant differences between main group and control group. All values were normal. It was estimated that increase in diuresis during use of Rowatinex contributes to effective and rapid passage of stone fragments. In addition, there was a decrease in leukocyturia in both groups. Conclusion. Drug Rowatinex allows to reduce the time to spontaneous passage of fragments after ESWL, intensity of pain syndrome and leukocyturia as well as to increase in daily diuresis. This is not accompanied by the development of complications and side effects which allows to administer Rowatinex for a long time as part of complex medical expulsive therapy and use it for recurrence prevention of urinary stone disease. Effect of Rowatinex didn’t depend on the stone composition.

Full Text

Restricted Access

About the authors

V. I Rudenko

FGAOU VO I.M. Sechenov First Moscow State Medical University of Minzdrav of Russia

Email: rudenko-vadim@rambler.ru
MD, professor at the Clinic of Urology and Male Reproductive Health

L. M Rapoport

FGAOU VO I.M. Sechenov First Moscow State Medical University of Minzdrav of Russia

Email: leonidrapoport@yandex.ru
MD, professor, deputy director of the Institute of Urology and Reproductive Health

Yu. L Demidko

FGAOU VO I.M. Sechenov First Moscow State Medical University of Minzdrav of Russia

Email: demidko1@mail.ru
MD, urologist at Institute of Urology and Reproductive Health

L. S Demidko

FGAOU VO I.M. Sechenov First Moscow State Medical University of Minzdrav of Russia

Email: klubnika47@yandex.ru
Ph.D. student, Institute of Urology and Reproductive Health

G. S Inoyatov

FGAOU VO I.M. Sechenov First Moscow State Medical University of Minzdrav of Russia

Email: inoyat@yandex.ru
urologist at Institute of Urology and Reproductive Health

S. N Allenov

FGAOU VO I.M. Sechenov First Moscow State Medical University of Minzdrav of Russia

Email: med-allen@yandex.ru
Head of LDO №4 UKB №2, Institute of Urology and Reproductive Health

References

  1. Fisang C., Anding R., Mtiller S.C., Latz S., Laube N. Urolithiasisan interdisciplinary diagnostic, therapeutic and secondary preventive challenge. Deutsches Arzteblatt International. 2015;112(6):83-91.
  2. Аляев Ю.Г., Руденко В.И., Газимиев М.А. Мочекаменная болезнь. Актуальные вопросы диагностики и выбора метода лечения. М.-Тверь: OOO «Издательство «Триада», 2006
  3. Черепанова Е.В., Дзеранов Н.К. Метафилактика мочекаменной болезни в амбулаторных условиях. Экспериментальная и клиническая урология. 2013; 3:33-39
  4. Дзеранов Н.К., Борисов В.В. Консервативная литокинетическая терапия камней почек и мочеточников. М.: Оверлей, 2009
  5. Голованов С.А., Дзеранов Н.К. Кристаллообразующая активность мочи при оксалатном уролитиазе. Экспериментальная и клиническая урология. 2010;2:24-29
  6. Дзеранов Н.К., Лопаткин Н.А. Мочекаменная болезнь: клинические рекомендации. М.: «Оверлей», 2007
  7. Сивков А.В., Черепанова Е.В., Шадеркина В.А. Применение фитопрепаратов на основе терпенов при мочекаменной болезни. Экспериментальная и клиническая урология. 2011;1:69-72
  8. Сивков А.В., Дзеранов Н.К., Черепанова Е.В., Константинова О.В., Голованов С.А., Шадеркина В.А. Результаты применения препарата Роватинекс у больных, страдающих уролитиазом. Экспериментальная и клиническая урология. 2011;4:38-45
  9. Ермоленко Т.И. Перспективы применения фитопрепаратов в лечении мочекаменной болезни. Фармация и фармакология. 2014;18:205-211
  10. Максимов В.А., Яровой С.К., Александров Н.С., Максудов Р.Р. Место фитотерапии в лечении мочекаменной болезни. Урология. 2012;3
  11. Sybilska D., Asztemborska M. Chiral recognition of terpenoids in some pharmaceuticals derived from natural sources. J. Biochem Biophys Methods. 2002;54(1-3):187-195.
  12. Chua M.E., Park J.H., Castillo J.C. Terpene compound drug as medical expulsive therapy for ureterolithiasis: a meta-analysis. Urolithiasis. 2013;41(2):143-151.
  13. Lee J.W., Lee M.Y., Park S.C. et al. In vitro Study on Ureteral Smooth Muscle Relaxation with Tamsulosin, Nifedipine, and Terpene mixure (Rowatinex). Eur. Urol. 2013;12(1) Supp.:17.
  14. Romics I., Siller G., Kohnen R., Mavrogenis S., Varga J., Holman E. A special terpenes combination (rowatinex®) improves stone clearance after extracorporeal shockwave lithotripsy in urolithiasis patients: results of a placebo-controlled randomized controlled trial. Urol Int. 2011;86(1):102-109.
  15. Djaladat H., Mahouri K., Khalifeh Shooshtary F., Ahmadieh A. Effect of Rowatinex on calculus clearance after extracorporeal shock wave lithotripsy. Urol. J. 2009;6(1):9-13.
  16. Попков В.М., Блюмберг Б.И., Основин О.В., Шатылко Т.В. Применение Роватинекса в периоперационном периоде при дистанционной ударно-волновой литотрипсии. Урология. 2012;2:25-27
  17. Азизов А.П. Применение Роватинекс в лечении хронического пиелонефрита, осложненного нефролитиазом. Фарматека. 2011;20:88-90
  18. Romics I., Kohnen R., Mavrogenis St., Varga J., Holman E., A Special Terpene Combination (Rowatinex) Improves Stone Clearance after Extracorporeal Shockwave Lithotripsy in Urolithiasis Patients: Results of a Placebo-Controlled Randomised Controlled Trial. Urologia Internationalis. 2011;86:102-109.
  19. Evan A.P., Worcester E.M., Coe FL., Williams J. Jr, Lingeman JE. Mechanisms of human kidney stone formation. Urolithiasis. 2015;43(Suppl 1):19-32.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies